<DOC>
	<DOCNO>NCT02034565</DOCNO>
	<brief_summary>The purpose study assess oral bioavailability Apixaban solution formulation ( Treatment B , 10 mg 25 mL x 0.4 mg/mL ) relative Apixaban tablet ( Treatment A , 10 mg 2 x 5 mg tablet ) healthy subject .</brief_summary>
	<brief_title>Phase 1 Bioavailability Study Apixaban Solution Formulation Relative Apixaban Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Any significant acute chronic medical illness relevant trauma ( e.g. , history chronic hypertension , bacterial endocarditis , hemorrhagic stroke , motor vehicle accident result significant head trauma internal injury ) History evidence abnormal bleed coagulation disorder ( e.g. , easy bruise gingival bleeding , prolong bleed dental extraction , postpartum , trauma , wound surgery )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>